The aim of the present study was to investigate PARP-1 expression and determine the existence of BRCA1 mutations in BC patients’ CTCs, with the ultimate goal of identifying biomarkers capable of guiding informed decisions regarding patients’ treatment, especially those of the more aggressive subtypes. The gene discussed is PARP1; the disease is breast cancer.